Effect of sacubitril/valsartan combined with creatine phosphate sodium in treatment of patients with heart failure with reduced ejection fraction

Objective To explore the clinical efficacy of sacubitril/valsartan combined with creatine phosphate sodium in heart failure patients with reduced ejection fraction (HFrEF).

Methods A total of 116 patients with HFrEF were randomly divided into combination group and control group, with 58 cases in each group. The control group was treated with sacubitril/valsartan, while the combination group was treated with sacubitril/valsartan and creatine phosphate sodium. Both groups were continually treated for 8 weeks. The clinical efficacy, oxidative stress indicators, cardiac function indicators, vascular endothelial function indicators and myocardial injury indicators before treatment and at 4 and 8 weeks after treatment as well as the occurrence of adverse reactions were compared between the two groups.

Results The total effective rate was 94.83% in the combination group, which was significantly higher than 81.03% in the control group (P < 0.05). At 4 and 8 weeks of treatment, the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) in the combination group were significantly lower than those in the control group, while the left ventricular ejection fraction (LVEF) was significantly higher than that in the control group (P < 0.01); the thromboxane B2 (TXB2) and endothelin-1 (ET-1) levels in the combination group were significantly lower than those in the control group, while the vascular endothelial growth factor (VEGF) level was significantly higher than that in the control group (P < 0.01); the levels of cardiac troponin Ⅰ (cTnⅠ), heart-type fatty acid-binding protein (H-FABP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in the combination group were significantly lower than those in the control group (P < 0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion Sacubitril/valsartan combined with creatine phosphate sodium has a definite therapeutic effect in treating patients with HFrEF, which can regulate the degree of oxidative stress, improve vascular endothelial function, and thus promote the recovery of cardiac function.